71 results about "Oxazepine" patented technology

The present invention relates to 1,4 Oxazepines of formula Ihaving BACE1 and / or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and / or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

The invention discloses an olanzapine-containing biodegradable microsphere preparation and a preparation method thereof. The olanzapine-containing biodegradable microsphere preparation comprises 10-50wt% of olanzapine or its salt, 0.5-20wt% of release adjusting agents and 30-89.5% of PLGA. In the invention, the PLGA having a proper monomer LA:GA ratio is selected as a matrix material, and above one release adjusting agents are added, so the olanzapine loading is improved to above 30%, and the particle size distribution and the in-vitro drug release of microspheres are improved. The utilization of a biodegradable material to encapsulate olanzapine to prepare the microspheres realizes a good slow release effect and the maintenance of an in-vivo relatively-stable drug concentration for above 15-45d or more.

The invention relates to the area of medicinal chemistry, pharmacology and medicine and includes description of pharmaceutical compositions and combined medicaments on the base of secretion stimulators and protectors of incretin hormones for treatment of metabolic diseases (among them, diabetes, obesity, metabolic syndrome and the like). The invention consists in that that pharmaceutical composition or combined medicament comprises a derivative of tetrahydrobenzo[f][1,4]oxazepine—either nonsteroidal agonist of bile aids receptor TGR5, or one of endogenous bile acids which stimulate incretin hormones secretion, and also one of the known inhibitors of DPP-IV proteinase. In this case administration of TGR5 agonists is carried out peroral, and administration of endogenous bile acids is exercised rectal in the form of suppository or gel. As proteinase DPP-IV inhibitors could be used Vildagliptin, Saxagliptin, Sitagliptin, Teneligliptin, Linagliptin, Dutogliptin, Alogliptin, Gemigliptin, Carmegliptin and the like. Besides, the invention includes description of novel tetrahydrobenzo[f][1,4]oxazepine derivatives—nonsteroidal agonist of bile aids receptors TGR5, and also methods for their preparation. The invention provides enhancement of therapy effectiveness owing to synergetic action of the components, thus making possible simultaneous treatment of diabetes, and obesity, other metabolic diseases and their cardiovascular and renal complications.

Compounds represented by the general formula (I):wherein each symbol is as defined in the description [with the proviso that 9-chloro-7-(1,1-dimethylethyl)-2,3,4,5-tetrahydro-1,4-benz-oxazepine and N-[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1,4-benz-oxazepin-7-yl)-5-oxazolidinyl]methyl]acetamide are excluded], salts of the same, and prodrugs thereof have selective activation effect on serotonin 5-HT2C receptor and are useful as preventive and therapeutic agents for lower urinary tract diseases, obesity, and / or pelvic organ prolapse.

An oral disintegrating tablet for effectively shielding the odor of oral cavity is prepared from the granulare odor-shielding medicine (estazolam, etc) and medicinal additive. Its advantages are short disintegrating time (less than 45 S) and high effect.

Described herein are antipyschotic compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; R1 is hydrogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH2CH2OH, —CN, imidazolidin-2-one, phenyl, or tetrazole wherein tetrazole is unsubstituted or substituted with (C1-4) alkyl; R2 is H, halogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, OR6, SR6, NO2, CN, COR6, C(O)OR6, C(OH)R6, CONR7R8, phenyl or (C1-6) alkyl, wherein the (C1-6) alkyl is unsubstituted or substituted with a hydroxy; R3 is hydrogen, (C1-6)fluoroalkyl , (C3-6) cycloalkyl, (C2-6) alkenyl, phenyl, monocyclic heteroaromatic, bicyclic heteroaromatic, or (C1-4)alkyl wherein (C1-4) alkyl is unsubstituted or substituted with a phenyl; R4 and R5 are independently selected from hydrogen, halogen, (C1-6) alkyl, (C1-6) fluoroalkyl, OR9, SR9, NO2, CN, or COR9; R6 is hydrogen, (C1-6) fluoroalkyl, or (C1-6) alkyl; R7 and R8 are independently hydrogen, or (C1-6) alkyl; R9 is hydrogen, (C1-6) fluoroalkyl, (C1-6) alkyl; Alk is (C1-4) alkylene unsubstituted or substituted with a hydroxy; Y is oxygen, sulfur, SO2, or a bond; X is CH2, C═O, S, O, or SO2; Z is hydrogen, halogen, (C1-6) alkyl, (C1-6)fluoroalkyl, —OH, (C1-6) alkoxy, (C1-6) fluoroalkoxy, (C1-6) alkylthio, (C1-6) acyl, (C1-4)alkylsulfonyl, —OCF3, —NO2, —CN, carboxamido which may be substituted on the nitrogen by one or two (C1-4) alkyl groups, and —NH2 in which one of the hydrogens may be replaced by a (C1-4) alkyl group and the other hydrogen may be replaced by either a (C1-4) alkyl group, a (C1-6) acyl group, or a (C1-4) alkylsulfonyl group; the phenyl of R1, R2 or R3 is independently unsubstituted or substituted with one to three substituents independently selected from Z; the monocyclic heteroaromatic of R3 is unsubstituted or substituted with one to three substituents independently selected from Z; the bicyclic heteroaromatic of R3 is unsubstituted or substituted with one to three substituents independently selected from Z; and salts, solvates, and crystal forms thereof. Also described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I).

Novel compounds of formula (I): suitable for use as in vivo imaging agents are provided as well as precursors suitable for the preparation of said compounds. The present invention also provides pharmaceuticals comprising the compounds and kits for the preparation of the pharmaceuticals. Furthermore, use of the compounds for imaging peripheral benzodiazepine receptors in a subject is provided, in particular for imaging pathological conditions in which PBR are upregulated, e.g. Parkinson's disease, multiple sclerosis, Alzheimer's disease and Huntington's disease, neuropathic pain, arthritis, asthma, atherosclerosis and cancer.

The invention discloses a polysubstituted benzo[b][1,4] oxazepine derivative and a preparation method thereof. The polysubstituted benzo[b][1,4] oxazepine derivative has the structural formula as shown in the description. The benzo[b][1,4] oxazepine derivative with multiple substituents, which cannot be synthesized by other methods, is synthesized, and profound and lasting significance is achieved from the angle of medical chemistry; the method has the advantages of easily available raw materials, high yield, mild reaction conditions, short reaction time, wide substrate range, strong reaction specificity, simple post-treatment and greenness.

The invention relates to a solid formulation for the oral administration of olanzapine that comprises a core of anhydrous olanzapine Form I or a pharmaceutically acceptable salt thereof and, optionally, pharmaceutically acceptable excipients, said core being coated with a functional polymer that acts as filmogenic agent. The method for obtaining it comprises: i) providing anhydrous olanzapine Form I or a salt thereof and, optionally, pharmaceutically acceptable excipients in solid form; ii) providing a functional polymer that acts as filmogenic agent; iii) preparing a dispersion of said functional polymer in an aqueous medium,—and applying the dispersion obtained in step iii) onto the solid form of step i).

The present invention relates to 1,4 Oxazepines of formula Ihaving BACE1 and / or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and / or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

The invention is directed to a novel method for making crystalline Form I of Olanzapine, wherein crude olanzapine is dissolved in a water-miscible solvent in which it is freely soluble, from which substantially pure polymorphic Form I of Olanzapine is recovered by precipitation.

The invention discloses a synthesis method of a pyrazolidinone-fused benzo 1,3-oxazepine compound, and belongs to the technical field of organic synthesis. 1-aryl pyrazolidinone 1 and a diazonaphthalene ketone compound 2 are used as raw materials, and in the presence of a catalyst, an oxidizing agent and an additive, a heating reaction is performed in an organic solvent to obtain the pyrazolidinone-fused benzo 1,3-oxazepine compound 3. According to the method, the pyrazolidinone-fused benzo 1,3-oxazepine compound is efficiently and regioselectively synthesized through cascade reaction between the 1-aryl pyrazolidinone compound and the diazonaphthalene ketone compound, and the method has the advantages that the raw materials are simple and easy to obtain, the operation is simple and convenient, the condition is mild, the selectivity is good, the substrate application range is wide, and the like.

The invention relates to an olanzapine composition and a preparation method thereof. The olanzapine composition consists of olanzapine, a diluent, a disintegrating agent and a lubricant. The olanzapine composition is simple in formula, few in auxiliary materials, more economical and low in production cost. The preparation method is simple, the powder fluidity of the preparation is good, large-scale production is easy, and the product is more stable.

The invention discloses an optical pure 7-amino-2,3,4,5-tetrahydrobenzo[b] [1,4]oxazepine-3-ol, wherein the structural formula of an R-type 7-amino-2,3,4,5-tetrahydrobenzo[b] [1,4]oxazepine-3-ol compound is as shown in a formula (I), and the structural formula of an S-type 7-amino-2,3,4,5-tetrahydrobenzo[b] [1,4]oxazepine-3-ol compound is as shown in a formula (II). The invention also discloses application of the compounds in inhibiting the activity of phosphatidylcholine-specific phospholipase C (PC-PLC). According to the optical pure 7-amino-2,3,4,5-tetrahydrobenzo[b] [1,4]oxazepine-3-ol provided by the invention, a situation that the R-type / S-type 7-amino-2,3,4,5- tetrahydrobenzo[b] [1,4]oxazepine-3-ol compound as an effective tool lays a foundation for the research on the activity inhibition of bacterial PC-PLC and the research, preparation and development of relevant human disease treatment drugs caused by PC-PLC is found.

The invention discloses tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine-one derivatives of which the structure is shown in a general formula of a figure in the abstract. The invention simultaneously discloses the preparation method of the tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine-one derivatives. The invention further discloses the application of the tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine-one derivatives as a reversible and selective monoamine oxidase inhibitor drug, specifically, the tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine can be applied to drugs or drug compositions for treating and preventing diseases related to aging, alzheimer's disease and parkinson's disease.

The invention discloses a 5-aryl-7-methoxycarbonyl dibenzo [b, e][1, 4] oxazepine-11(5H)-ketone compound and a preparation method thereof. The preparation method comprises the steps of carrying out condensation, isomerization and dehydration reaction on 3-dehydrogenated methyl shikimate and an aryl amine compound in the presence of an organic solvent and a catalyst in the microwave condition to obtain an aryl-substituted o-aminophenol intermediate; further adding o-halogen benzoic acid and an alkali neutralization catalyst in the microwave condition, cooling, pumping filtering, and carrying out recrystallization to obtain an N, N-diaryl-substituted o-aminophenol intermediate; and in the organic solvent, carrying out molecular lactonization cyclization reaction on the N, N-diaryl-substituted o-aminophenol intermediate in the presence of the catalyst and alkali to obtain the 5-aryl-7-methoxycarbonyl dibenzo [b, e][1, 4] oxazepine-11(5H)-ketone compound. The preparation method is simple, is short in the reaction time, is convenient for postprocessing and is high in the yield.

The invention discloses a synthetic method of an oxazepine [3, 2-b] indole compound, and belongs to the technical field of organic synthesis. The synthetic method comprises the following steps: performing [4 + 3] cycloaddition reaction on a crotonate-derived sulfur ylide reagent shown as a formula (2) and a 3-oxindolone substrate shown as a formula (1) under an alkaline condition to obtain the oxazepine [3, 2-b] indole compound shown as a formula (3), the invention also provides the oxazepine [3, 2-b] indole compound. The synthetic method is simple, convenient and efficient, large instrumentsand expensive raw materials are not needed, the reaction conditions are mild, the derivatization range of the substrate is wide, and a foundation is laid for industrial production.

The invention relates to a 6, 7, 8, 9-tetrahydro-[1, 4]oxazepine[3, 2-g] quinazoline derivative with a structure shown as formula I, tautomers, stereisomers and pharmaceutically acceptable salts thereof, especially pharmaceutically acceptable salts formed by the derivative and inorganic or organic acids or alkalis, and also relates to a preparation method, and application of the receptor tyrosine kinase inhibition property of the compounds in preparation of drugs treating proliferative diseases like cancer. (formula I).

The invention belongs to the technical field of medicine synthesis, and discloses a synthesis method of olanzapine related substances like namely a compound I and a compound II. The preparation methodcomprises the following steps: S1, synthesis of a compound I: adding olanzapine, an organic solvent and water into a reaction flask, sequentially adding Oxone and sodium hydroxide, continuously reacting until olanzapine spots disappear, then adjusting the pH of the system to 6-7, and carrying out extraction and recrystallization to obtain the compound I; S2, synthesis of a compound II: dissolvingthe compound I in an organic solvent, adding inorganic alkali liquor at 0 DEG C, then adding acetyl chloride, continuing to stir and react at 0 DEG C until the compound I disappears, carrying out liquid separation extraction, and carrying out silica gel column chromatography purification to obtain the compound II. The preparation method provided by the invention has the advantages of short reaction route, mild conditions, low overall cost and high yield and purity, and provides reliable material guarantee for subsequent quality control research and safety property research in the olanzapine preparation process.

The invention discloses an olanzapine-fluoxetine compound capsule preparation and a preparation method thereof, which are used for the drug treatment of bipolar affective disorder. The compound preparation contains two different pellets, which are respectively enteric-coated olanzapine-containing Flat sustained-release pellets and gastric-soluble fluoxetine-containing sustained-release pellets; the olanzapine-fluoxetine compound capsule preparation of the present invention is combined according to the different in vivo pharmacokinetic laws of olanzapine and fluoxetine Two types of pellets with different ratios and different release parts complete the preparation of products of different specifications; achieve rapid onset of effect, synergistic effect, and reduce the number of times of taking medicine.

The invention relates to an improved ketoreductase and belongs to the technical field of biocatalytic synthesis. The ketoreductase mutant of the present invention, the amino acid sequence of the ketoreductase mutant is an amino acid sequence in which the amino acid sequence shown in SEQ ID NO: 1 is mutated, and the mutation sites of the mutated amino acid sequence are respectively: position 140 I is mutated to S, and the optional mutation points include at least one of the following points: the 205th D mutation to E, the 125th H mutation to Q, the 329th N mutation to S, and the 294th L mutation to I. The 150th D is mutated to Q, and the 36th P is mutated to S. The invention provides a ketoreductase and application thereof, which can effectively reduce (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1 , 3-oxazolane-2-one and the cost of industrial production of ezetimibe.

Belonging to the field of medical technology, the invention specifically relates to a new preparation method of a DGAT1 inhibitor 4-amino-6-(3, 5-dimethyl-4-(3-methyl-1-(2, 2, 2-trifluoroethyl)-1H-pyrazole-4-yl)phenyl)-7, 8-dihydropyrimidine[5, 4-f][1, 4]oxazepine-5(6H)-one-hydrochloride. The method includes: taking 3, 5-dimethyl-4-(3-methyl-1-(2, 2, 2-trifluoroethyl)-1hydro-pyrazole-4-yl)aniline-hydrochloride as the starting raw material for condensation reaction with chloroethyl chloroformate to generate an intermediate 1; alkylating the intermediate 1 in an alcohol and alkali solution and then performing hydrolysis to generate an intermediate 2; subjecting the intermediate 2 to condensation reaction with 4, 6-dichloropyrimidine-5-acyl chloride to generate an intermediate 3; alkylating the intermediate 3, then carrying out intramolecular ring closure reaction to generate an intermediate 4; subjecting the intermediate 4 to ammoniation in a dioxane solution of ammonia to generate an intermediate 5; and subjecting the intermediate 5 to salt formation in an acetone solution to obtain a finished product. All the reaction intermediates involved in the invention are all solids, thus being easy for purification.

The invention discloses a preparation method of an oxazepine compound, and particularly discloses a preparation method and an intermediate of a compound shown as a formula (I) in the specification.